News
Use of Targeted Therapy with Dupilumab in Patients with Allergic Diseases
Interleukins (IL) 4 and 13 play an important role in the pathogenesis of allergic diseases. Their blockade is therefore a suitable strategy for a number of these conditions. This is offered by the new monoclonal antibody dupilumab (Dupixent), which is approved for the treatment of atopic dermatitis, asthma with type 2 inflammation, and chronic rhinosinusitis with nasal polyposis. Studies are ongoing to evaluate its efficacy in other diseases where type 2 inflammation predominates.
Fixed Combination of Tramadol/Paracetamol in the Treatment of Chronic Lower Back Pain and Its Effect on Apathy in Chronically Algic Patients
Long-term chronic pain is associated with apathy, loss of motivation, and depression in patients.…
Can the Fixed Combination of Tramadol/Acetaminophen Significantly Reduce Back Pain Uncontrolled by NSAIDs?
One way to prevent drug-related complications in the treatment of lower back pain (LBP) while…
Brentuximab Vedotin and Relapsing/Refractory NHL with High Expression of CD30
A recently published study by authors from South Korea focused on examining the efficacy of…
New Natural Method for Prevention and Treatment of House Dust Mite Allergy
House dust mites are among the most common triggers of respiratory allergies. Until now, therapy…
Comparison of Pharmacological Properties of Micronized Diosmin and Hesperidin in the Treatment of Chronic Venous Insufficiency and Hemorrhoids
Diosmin and hesperidin belong to the group of bioflavonoids, which currently find wide application…
Topically administered tacrolimus does not increase cancer risk in children with atopic dermatitis
Topical therapy using corticosteroids or calcineurin inhibitors forms the main component of…
Are Topical Calcineurin Inhibitors Really Such Demons?
Some medications indeed have significant side effects, while others suffer from a bad reputation…
Case Study of a Patient with NSCLC − with Voting
Presented by: MUDr. Leona Koubková,
Pneumology Clinic, 2nd Faculty of Medicine, Charles University...
Dupilumab – The First Biologic Umbrellaing Type 2 Inflammation Treatment: How Does It Work and Who Is It For?
A new drug is entering the market for the treatment of atopic dermatitis, asthma, and chronic…